Aprea Therapeutics Appoints Mirza As CMO
Press Release: Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) New role enhances company's stron
Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating
Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis
Aprea Therapeutics Announces Presentations on Its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ
Aprea Therapeutics Files to Sell 4.39M Shares of Common Stock for Holders
Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics with a Outperform and raises the price target from $9 to $11.
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024
HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics with a Buy and maintains $20 price target.
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
US stocks looked set to open modestly higher Tuesday as investors parsed durable goods and home price data and looked ahead to a key consumer confidence gauge. Dow Jones Industrial Average futures wer
Aprea Therapeutics: Q4 Earnings Insights
Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings results on Tuesday, March 26, 2024 at 07:45 AM.Here's what investors need to know about the announcement.EarningsAprea Therapeutics missed est
Aprea Therapeutics GAAP EPS of -$0.92
Aprea Therapeutics 4Q Loss/Shr 92c >APRE
Aprea Therapeutics 4Q Loss/Shr 92c >APRE
Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline
No Data